Ambrx raises $45M to back bioconjugates in the clinic

China flag

Ambrx has been around since it was founded in 2003. Now, the San Diego, CA-based startup has raised a latest financing of $45 million to support Phase I testing of its lead candidate, ARX788 to treat HER2-positive breast cancer.

Last year, a handful of Chinese biopharmas and investors stepped in to buy Ambrx with an eye toward making it a prominent collaborator for companies in that country. They included Fosun Pharma, CRO WuXi and investors China Everbright and HOPU Investments. Ambrx had tried to go public in 2014, but withdrew the IPO instead.

The latest cash infusion will go to advance ARX788 in the clinic, as well as to get other Ambrx antibody-drug conjugates (ADCs) into clinical trials--including its lead immuno-oncology program CD3-Folate.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

"The new investors along with our existing investors brought together a perfect combination of strategic pharmaceutical investments as well as top tier private financial investments. This clearly shows the confidence from the investors in the Ambrx technology platform for its broad impact and great potential in biological drug development," said Ambrx CEO Alex Qiao in a statement.

He added, "The new funding resources will allow us to accelerate the development of our programs, and to make improvements to our technology platform."

The latest financing was led by seed stage investor Apricot Capital and Northeast Securities Prosperity Healthcare Fund. Sinopharm Capital, Humanwell Healthcare Fund also participated alongside existing investors Fosun Pharma, HOPU Investments and Everbright participated in the financing.

Ambrx uses its ReCode bacterial technology to create long-acting therapeutic peptides and proteins as well as modified antibody and bispecific fragments. It uses its EuCode tech to create larger and more complex proteins where the function depends on post-translation modification.

Over the years, Ambrx has racked up more than $200 million in milestone payments from its partners who include Bristol-Myers Squibb ($BMY), Merck ($MRK), Astellas, Eli Lilly ($LLY) and Zhejiang Hisun Pharmaceutical.

- here is the release

Related Articles:
Chinese drugmakers snag antibody expert Ambrx in joint buyout
Bristol-Myers' armed antibody partner Ambrx shoots for an $86M IPO
Astellas, Ambrx seal $300M cancer ADC deal
Ambrx taps WuXi for HER2-targeting cancer drug

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.